Evidence map›Paper›PMID 41977382›Full record

ArticleInternational journal of molecular sciences2026

Lycium Barbarum Polysaccharide Antagonizes Cardiomyocyte Pyroptosis by Inhibiting the Nrf2/NLRP3 Signal Pathway Against Myocardial Ischemia-Reperfusion Injury.

Liuxin Wu, Peng Lin, Xiaomeng Yin, Lin Yang, Chunyan Ma, Shulin Wu, Moyan Yang, Guangyuan Yang, Mingyuan Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Liuxin WuSchool of Pharmaceutical Sciences, Jiamusi University, Jiamusi 154003, China.
Peng LinSchool of Pharmaceutical Sciences, Jiamusi University, Jiamusi 154003, China.
Xiaomeng YinSchool of Pharmaceutical Sciences, Jiamusi University, Jiamusi 154003, China.
Lin YangSchool of Basic Medical Sciences, Jiamusi University, Jiamusi 154003, China.
Chunyan MaSchool of Basic Medical Sciences, Jiamusi University, Jiamusi 154003, China.
Shulin WuSchool of Basic Medical Sciences, Jiamusi University, Jiamusi 154003, China.
Moyan YangSchool of Pharmaceutical Sciences, Jiamusi University, Jiamusi 154003, China.
Guangyuan YangSchool of Basic Medical Sciences, Jiamusi University, Jiamusi 154003, China.
Mingyuan LiuSchool of Basic Medical Sciences, Jiamusi University, Jiamusi 154003, China.

Funding

Education Department of Heilongjiang Province 2024-KYYWF-0612Heilongjiang Chinese Medicine Administration ZHY2024-094Heilongjiang Provincial Natural Science Foundation of China LH2024H005Jiamusi University DJXSTD202409Jiamusi University JMSUGPZR2023-013
6 · The paper itself

Abstract

Myocardial ischemia-reperfusion injury (MIRI) significantly compromises the clinical benefits of revascularization and constitutes a central pathological mechanism worsening prognosis in myocardial infarction patients. Accordingly, dissecting the molecular mechanisms underlying MIRI and formulating effective therapeutic interventions are of great clinical significance.

Indexed as

Drugs, Chinese HerbalMyocardial Reperfusion InjuryMyocytes, CardiacNF-E2-Related Factor 2NLR Family, Pyrin Domain-Containing 3 ProteinPyroptosisSignal TransductionAnimalsCell LineMaleOxidative StressRatsRats, Sprague-DawleyDrugs, Chinese Herballycium barbarum polysaccharideNfe2l2 protein, ratNF-E2-Related Factor 2NLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, ratLycium barbarum polysaccharidemyocardial ischemia reperfusion injuryNLRP3 inflammasomeNrf2/NLRP3 signal pathwayoxidative stresspyroptosis

Identifiers

PMID41977382
PMCPMC13073030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.